How Lipitor Targets HMG-CoA Reductase
Lipitor (atorvastatin) inhibits HMG-CoA reductase, the enzyme that limits the rate of cholesterol synthesis in the liver. This protein converts HMG-CoA to mevalonate, the first step in the mevalonate pathway producing cholesterol and other isoprenoids.[1]
What Happens When Lipitor Blocks This Protein
By binding competitively to HMG-CoA reductase's active site, Lipitor reduces cholesterol production, prompting the liver to increase LDL receptor expression on cell surfaces. This pulls more LDL cholesterol from the blood, lowering circulating levels.[1][2]
Other Proteins Affected Downstream
Inhibiting HMG-CoA reductase cuts mevalonate, depleting isoprenoids needed for prenylation—modifying small GTPases like Rho, Rac, and Ras. This disrupts their membrane anchoring and signaling, contributing to Lipitor's anti-inflammatory and plaque-stabilizing effects beyond cholesterol reduction.[2][3]
Clinical Evidence on Protein Impact
Trials like the TNT study showed atorvastatin reduces cardiovascular events by altering lipid metabolism via HMG-CoA reductase inhibition, with downstream effects on vascular proteins confirmed in proteomic analyses.[4]
[1]: FDA Label for Lipitor
[2]: Nature Reviews Drug Discovery - Statins mechanism
[3]: Circulation Research - Pleiotropic effects
[4]: New England Journal of Medicine - TNT Trial